Clearside Biomedical, a biopharmaceutical company based in Alpharetta, Georgia, is poised to shake up the world of eye therapies. The company is leading the charge to revolutionize the delivery of treatments to the back of the eye through the suprachoroidal space. Clearside's flagship product, XIPERE, is a triamcinolone acetonide suprachoroidal injectable suspension that is currently being used to treat uveitis macular edema. The company is also developing CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which is currently in Phase 1/2a clinical trial. Additionally, Clearside is working on CLS-301, an integrin inhibitor suspension for the treatment of diabetic macular edema and macular degeneration. Clearside has strong partnerships with top players in the biopharmaceutical industry, including Bausch Health, Arctic Vision, REGENXBIO, and Aura Biosciences. Clearside Biomedical was founded in 2011 and remains at the forefront of innovation in the field of biopharmaceuticals.